Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Adopts Shareholder Rights Plan

NEW YORK, June 20 - Luminex said Wednesday its board of directors has adopted a shareholders rights plan designed to prevent hostile takeover bids.

Luminex, an Austin, Texas-based developer of microarray bead technology, said that the decision to adopt the rights plan was not a reaction to any outside attempt to takeover the company.

"The adoption of the rights plan is merely a means of safeguarding against abusive takeover tactics and is not in response to any accumulation of shares or hostile takeover attempt,” Mark Chandler, Luminex’s CEO said in a statement.

“In fact, we are not aware of any effort to acquire the company,” Chandler said.

The rights plan has a 20 percent trigger, meaning that it will only go into effect if an outside party accumulates 20 percent or more of the company’s stock.

Recently, several companies, including Informax, Orchid BioSciences, Aclara,  Large Scale Biology, and Illumina,  have all adopted such plans.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.